List view / Grid view
30 November 2015 | By Victoria White
Heptares and Pfizer have announced they are to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas...
8 September 2015 | By Victoria White
AMRA will collaborate with Pfizer to help provide a better understanding of the relationship between body composition and risk for obesity related diseases...
18 August 2015 | By The European Antibody Congress
The European Antibody Congress takes place 9-11 November 2015 at the Congress Centre, Basel...
8 July 2015 | By Victoria White
Pfizer’s Centres for Therapeutic Innovation and the Jeffrey Modell Foundation are to collaborate to conduct research in the field of immunological diseases...
7 May 2015 | By Victoria White
Pfizer has made two strategic appointments in the leadership of their BioTherapeutics Research and Development and Rinat units...
9 April 2015 | By Victoria White
Pfizer has launched a new competitive grants programme to support research projects investigating the role of PCSK9 in health and cardiovascular disease...
7 April 2015 | By Victoria White
Pfizer announces that Kathrin Jansen has been appointed Senior Vice President, Vaccine Research & Development, and will report directly to Mikael Dolsten...
31 March 2015 | By Victoria White
Pfizer Inc. has announced that Charles Reay Mackay will join the company as Chief Scientific Officer for Pfizer’s Inflammation and Immunology Research Unit...
5 January 2015 | By Pfizer
Acquisition provides Pfizer with a preclinical CMV vaccine candidate...
10 December 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis (apixaban) by 4-factor prothrombin complex concentrates (PCCs) in healthy subjects...
26 September 2014 | By Pfizer
Pfizer Inc. announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States (U.S.) regulatory approval from all government authorities required by the agreement and other closing conditions...
27 August 2014 | By Pfizer
Pfizer Inc. and Merck & Co. Inc. through a subsidiary, announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib (XALKORI®) with MSD’s investigational anti-PD-1 antibody pembrolizumab...
17 July 2014 | By Pfizer
Pfizer Inc. and InnoPharma, Inc. announced that they have entered into an agreement under which Pfizer will acquire InnoPharma...
18 June 2014 | By Pfizer
Pfizer Inc. and Cellectis announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets...
23 May 2014 | By Pfizer
Pfizer Inc. announced detailed results from the Oral treatment Psoriasis Trial Retreatment study, a Phase 3 study investigating tofacitinib for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis...
